Wedbush Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
In a report released today, from Wedbush maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $18.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Wedbush, Apellis Pharmaceuticals also received a Hold from TipRanks – Google’s Google Biotechnology in a report issued today. However, on the same day, Citi maintained a Buy rating on Apellis Pharmaceuticals (NASDAQ: APLS).
Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $458.58 million and a net profit of $215.72 million. In comparison, last year the company earned a revenue of $196.83 million and had a GAAP net loss of $57.45 million
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year. Earlier this month, Mark Jeffrey DeLong, the Chief Business & Strat Officer of APLS sold 368.00 shares for a total of $8,151.20.
Read More on APLS:
Disclaimer & DisclosureReport an Issue
- Apellis price target lowered to $44 from $45 at Citi
- Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
- Apellis price target raised to $48 from $45 at H.C. Wainwright
- Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise
- Apellis Pharmaceuticals: Solid Syfovre Franchise and Rapid Empaveli Uptake Underpin Buy Rating and Long-Term Upside
